Representative series of older patients treated for Hodgkin lymphoma.
| Regimen . | COPP-ABVD or BEACOPP . | COPP . | CHOP-21 . | BEACOPP . | VEPEMB . | ODBEP . |
|---|---|---|---|---|---|---|
| Number | 372 | 52 | 29 | 42 | 105 | 38 |
| Median age, y | 65 | — | — | 68 | 71 | 72 |
| % with major co-morbidity | — | — | 55 | — | 37 | — |
| Stage – limited, % | 34 | 16 | 38 | 0 | 46 | 0 |
| Stage – advanced, % | 66 | 84 | 62 | 100 | 54 | 100 |
| Febrile neutropenia, % | 15 | 6 | 31 | — | 10 | 14 |
| Compete response, % | 86 | — | 93 | 76 | 76 | — |
| Median follow-up, mos | — | 60 | 41 | 80 | — | — |
| Progression-free survival, | % 60 (5-y) | — | 76 (3-y) | 46 (5-y) | 56 (5-y) | 49 (5-y) |
| Overall survival, % | 65 (5-y) | 48 (5-y) | 79 (3-y) | 50 (5-y) | 64 (5-y) | 42 (5-y) |
| Fatal toxicity, % | 6 | — | — | 21 | 2 | — |
| Reference | 50 | 49 | 63 | 59 | 58 | 52 |
| Regimen . | COPP-ABVD or BEACOPP . | COPP . | CHOP-21 . | BEACOPP . | VEPEMB . | ODBEP . |
|---|---|---|---|---|---|---|
| Number | 372 | 52 | 29 | 42 | 105 | 38 |
| Median age, y | 65 | — | — | 68 | 71 | 72 |
| % with major co-morbidity | — | — | 55 | — | 37 | — |
| Stage – limited, % | 34 | 16 | 38 | 0 | 46 | 0 |
| Stage – advanced, % | 66 | 84 | 62 | 100 | 54 | 100 |
| Febrile neutropenia, % | 15 | 6 | 31 | — | 10 | 14 |
| Compete response, % | 86 | — | 93 | 76 | 76 | — |
| Median follow-up, mos | — | 60 | 41 | 80 | — | — |
| Progression-free survival, | % 60 (5-y) | — | 76 (3-y) | 46 (5-y) | 56 (5-y) | 49 (5-y) |
| Overall survival, % | 65 (5-y) | 48 (5-y) | 79 (3-y) | 50 (5-y) | 64 (5-y) | 42 (5-y) |
| Fatal toxicity, % | 6 | — | — | 21 | 2 | — |
| Reference | 50 | 49 | 63 | 59 | 58 | 52 |